The founder started Interface Biologics to commercialize three platform technologies developed at the University of Toronto: Endexo, Epidel, and Kinesyx. These technologies provide drug-eluting coatings for medical devices to improve clinical outcomes. He took a role as CSO and President of Interface Biologics from 2001-2004, financing the startup with $1 million and incubating it at UOT. In 2004, the company received $10 million in venture financing. He has remained as Associate Dean at UOT to maintain links between the university resources and Interface Biologics' R&D program.